Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein
about
Determinants of early life immune responses to RSV infectionStable long-term cultures of self-renewing B cells and their applicationsStructure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial VirusStructural and molecular basis for Ebola virus neutralization by protective human antibodiesDiscovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F GlycoproteinA novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein.A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuationAntigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins.A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSVStability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSVVaccines against respiratory syncytial virus: The time has finally come.Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.Immunogenicity of RSV F DNA Vaccine in BALB/c Mice.Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus.Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donorsPotent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells.Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.Structural and Nonstructural Viral Proteins Are Targets of T-Helper Immune Response against Human Respiratory Syncytial Virus.Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.Protection of calves by a prefusion-stabilized bovine RSV F vaccine.Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV.Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape.Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit are Critical for its Fusion Activity.Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset
P2860
Q26764790-E043AEFA-B7A6-4FFE-B4DB-D454D2229B77Q26766723-01DE0F5D-B4F7-4912-A133-0143ACAA1B14Q27333522-2A9D22E9-3152-47B3-8751-F24299B063DCQ27704188-217268EC-F302-4ADF-9696-870326C95D30Q28552644-52134EDE-0162-481C-940E-12B90AC92127Q33775790-625F5D5C-2955-4A7F-B8D8-72D43662DBD6Q34547769-1AB1557C-F961-4367-B590-7E01EBB21749Q35995788-6118A4DF-C99B-4D8D-9776-1BECCBC6E4DBQ36029158-C363AC28-AB07-419A-B7E3-F1EDFAA413A1Q36169170-B7762397-664A-44D7-AABB-1F0209C30B1BQ36348462-27D0A91C-D272-49C0-A7DD-B8B5765C76C8Q36353767-97BBAC8A-34A1-4BFD-8DF9-F8E5D752D3D8Q36973952-EF5412EC-88CB-483A-933A-A8F59AFC51EFQ37002523-6E407704-F8DC-4FE3-9C59-F55203DD70C9Q37018347-3DC01597-36C9-4BB7-959F-E51B4173A056Q37069783-F28ADBB1-515E-44C3-A2F1-185FF6331CA7Q37242530-0AF71D9B-3A06-419B-8797-07224F951CA5Q37263840-4AE4FB82-5EB0-46EB-9337-7C4FD8A0C0C9Q37293748-7ECDB2B2-1418-4851-9492-0DB67BE62D68Q37347267-3EEE7B86-D3DB-40A5-B244-246A09C6808BQ37398188-40FEFF6F-705E-43A9-BF5B-F28500240A23Q37536191-281B1381-01B7-4776-A502-93191948CA67Q37593886-6F5A4EDF-B663-4AA9-826B-5C265BD83446Q37651813-B94082EA-A01B-47D0-BFC0-E6D67F995DD9Q38628928-7BF36AB3-3784-4BE9-99DF-A6B58B682974Q38750689-331B8F3F-23B2-42A2-B182-18216F9CE6B4Q38969434-605C108B-DA47-49CE-B079-260D3231FC79Q40187606-8B09059C-EBA5-4D08-AD99-18910406A2D0Q40216493-368511F6-1BDF-4833-9B7E-CFFA5BBA7819Q40216566-47903FA5-A441-4583-AB6F-FA1C89CC29AAQ40301211-87E91176-E8C5-4AA8-8546-88C16F9E7ED5Q40353525-D843AA96-EE1F-4C25-840A-0F202EB25EE0Q40709475-2A3FF35D-D294-495B-92A8-DF5104842550Q40812866-7C0EC2EA-F4FE-46D6-9313-6F7C04307B42Q41918616-B55B7FF1-C002-4FC7-A674-B49D9E8F01D0Q42652733-3C32A5D4-3DF2-4776-BC94-14D4731E200AQ50422323-DE8BEA51-09F0-4B1C-AF06-13D7F871ADB3Q51149122-761B3C39-7119-4769-94E9-45C0958606F4Q54216743-8F0B42B9-85B4-4C91-9A54-15DE64955FB4Q57189137-B9C28574-1CA6-4E11-8CC2-14BB932FA825
P2860
Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Characterization of a Prefusio ...... on the RSV Fusion Glycoprotein
@ast
Characterization of a Prefusio ...... on the RSV Fusion Glycoprotein
@en
type
label
Characterization of a Prefusio ...... on the RSV Fusion Glycoprotein
@ast
Characterization of a Prefusio ...... on the RSV Fusion Glycoprotein
@en
prefLabel
Characterization of a Prefusio ...... on the RSV Fusion Glycoprotein
@ast
Characterization of a Prefusio ...... on the RSV Fusion Glycoprotein
@en
P2093
P2860
P50
P1433
P1476
Characterization of a Prefusio ...... on the RSV Fusion Glycoprotein
@en
P2093
Azad Kumar
Barney S Graham
Kari Kramer
Morgan S A Gilman
Nancy D Ulbrandt
Nita K Patel
Stephanie C Kabeche
Tim Beaumont
P2860
P304
P356
10.1371/JOURNAL.PPAT.1005035
P577
2015-07-10T00:00:00Z